P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847432.95668.eb |
| _version_ | 1797287270070353920 |
|---|---|
| author | A. Tivey R. Shotton T. A. Eyre D. Lewis N. Crosbie E. Nga R. Guerrero Camacho W. Swe H. Marr C. Rees S. Moule T. Sutton D. Wrench N. Thomas M. Wilson J. Bailey M. Prahladan A. Hodson M. Koppana S. Smith S. Jones F. Miall J. Norman E. Davies C. Hildyard L. Lowry S. Paneesha I. Qureshi A. Beech C. Bedford A. Everden D. Tucker J. Wright J. Goddard T. Nicholson J. Wilson A. Lord B. Jackson M. Flont A. Gibb K. Linton |
| author_facet | A. Tivey R. Shotton T. A. Eyre D. Lewis N. Crosbie E. Nga R. Guerrero Camacho W. Swe H. Marr C. Rees S. Moule T. Sutton D. Wrench N. Thomas M. Wilson J. Bailey M. Prahladan A. Hodson M. Koppana S. Smith S. Jones F. Miall J. Norman E. Davies C. Hildyard L. Lowry S. Paneesha I. Qureshi A. Beech C. Bedford A. Everden D. Tucker J. Wright J. Goddard T. Nicholson J. Wilson A. Lord B. Jackson M. Flont A. Gibb K. Linton |
| author_sort | A. Tivey |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:30:33Z |
| format | Article |
| id | doaj.art-f375cd65d33b401cb3070541f0b1496b |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:30:33Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-f375cd65d33b401cb3070541f0b1496b2024-03-02T06:40:32ZengWileyHemaSphere2572-92412022-06-0161031103210.1097/01.HS9.0000847432.95668.eb202206003-01031P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDYA. Tivey0R. Shotton1T. A. Eyre2D. Lewis3N. Crosbie4E. Nga5R. Guerrero Camacho6W. Swe7H. Marr8C. Rees9S. Moule10T. Sutton11D. Wrench12N. Thomas13M. Wilson14J. Bailey15M. Prahladan16A. Hodson17M. Koppana18S. Smith19S. Jones20F. Miall21J. Norman22E. Davies23C. Hildyard24L. Lowry25S. Paneesha26I. Qureshi27A. Beech28C. Bedford29A. Everden30D. Tucker31J. Wright32J. Goddard33T. Nicholson34J. Wilson35A. Lord36B. Jackson37M. Flont38A. Gibb39K. Linton401 Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester1 Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester2 Oxford University Hospitals NHS Foundation Trust, Oxford3 University Hospitals Plymouth NHS Foundation Trust, Plymouth3 University Hospitals Plymouth NHS Foundation Trust, Plymouth4 Airedale NHS Foundation Trust, Airedale5 Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool6 Calderdale and Huddersfield NHS Foundation Trust, Huddersfield7 The Freeman Hospital, Newcastle8 Frimley Health NHS Foundation Trust, Frimley8 Frimley Health NHS Foundation Trust, Frimley9 Gateshead Health NHS Foundation Trust, Gateshead10 Guy’s and St Thomas’ NHS Foundation Trust, London, London11 Harrogate and District NHS Foundation Trus, Harrogate11 Harrogate and District NHS Foundation Trus, Harrogate12 Hull University Teaching Hospitals NHS Trust, Hull13 East Suffolk and North Essex NHS Foundation Trust, Ipswich13 East Suffolk and North Essex NHS Foundation Trust, Ipswich13 East Suffolk and North Essex NHS Foundation Trust, Ipswich14 Sherwood Forest Hospitals NHS Foundation Trust, Sutton in Ashfield14 Sherwood Forest Hospitals NHS Foundation Trust, Sutton in Ashfield15 University Hospitals of Leicester NHS Foundation Trust, Leicester16 Manchester University NHS Foundation Trust, Manchester16 Manchester University NHS Foundation Trust, Manchester17 Milton Keynes University Hospital, Milton Keynes18 Somerset NHS Foundation Trust, Taunton19 University Hospitals Birmingham NHS Foundation Trust, Birmingham19 University Hospitals Birmingham NHS Foundation Trust, Birmingham20 Nottingam University Hospitals, Nottingham21 Royal Cornwall Hospitals NHS Trust, Truro21 Royal Cornwall Hospitals NHS Trust, Truro21 Royal Cornwall Hospitals NHS Trust, Truro22 Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield22 Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield23 St Helens & Knowsley Teaching Hospitals NHS Trust, Whiston24 University Hospitals Sussex NHS Foundation Trust, Chichester25 Torbay and South Devon NHS Foundation Trust, Torbay25 Torbay and South Devon NHS Foundation Trust, Torbay26 York and Scarborough Teaching Hospitals NHS Foundation Trust, York27 Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, Manchester, United Kingdom27 Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, Manchester, United Kingdomhttp://journals.lww.com/10.1097/01.HS9.0000847432.95668.eb |
| spellingShingle | A. Tivey R. Shotton T. A. Eyre D. Lewis N. Crosbie E. Nga R. Guerrero Camacho W. Swe H. Marr C. Rees S. Moule T. Sutton D. Wrench N. Thomas M. Wilson J. Bailey M. Prahladan A. Hodson M. Koppana S. Smith S. Jones F. Miall J. Norman E. Davies C. Hildyard L. Lowry S. Paneesha I. Qureshi A. Beech C. Bedford A. Everden D. Tucker J. Wright J. Goddard T. Nicholson J. Wilson A. Lord B. Jackson M. Flont A. Gibb K. Linton P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY HemaSphere |
| title | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_full | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_fullStr | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_full_unstemmed | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_short | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_sort | p1141 ibrutinib and rituximab as first line therapy for mantle cell lymphoma a multicentre real world uk study |
| url | http://journals.lww.com/10.1097/01.HS9.0000847432.95668.eb |
| work_keys_str_mv | AT ativey p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT rshotton p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT taeyre p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT dlewis p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT ncrosbie p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT enga p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT rguerrerocamacho p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT wswe p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT hmarr p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT crees p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT smoule p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT tsutton p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT dwrench p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT nthomas p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT mwilson p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT jbailey p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT mprahladan p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT ahodson p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT mkoppana p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT ssmith p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT sjones p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT fmiall p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT jnorman p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT edavies p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT childyard p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT llowry p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT spaneesha p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT iqureshi p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT abeech p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT cbedford p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT aeverden p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT dtucker p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT jwright p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT jgoddard p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT tnicholson p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT jwilson p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT alord p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT bjackson p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT mflont p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT agibb p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT klinton p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy |